Independent analysis puts a HJ dulaglutide lot at 98.7%, against 96.2% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
July 2025 — Vol. 2, No. 7
Page 4 of 4 of this archive, newest first.
Also filed — page 4
the rolling newsroom, July 2025What changed at QST in July, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What the new Nigeria guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Chengdu: 20 posters, one theme
Reported from the sessions, and from the two hours afterwards.
South Korea health authority warns on falsified tirzepatide pens
Reported from the analysis, not from a warning notice.
Hong Kong export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Ireland pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
PeptideMeter result on a Hong Kong mazdutide lot lands 2.6 points below the supplier’s figure
The result is unremarkable. What the report omits is not.
The quiet end of the online reseller trading as Adamant Research Supply
A proper account of an operation that existed, and of what closing it cost.
A shortage listing ends. 9 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Sweden health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
From the floor in Shanghai: 12 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
SURMOUNT-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Switzerland pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Zhuhai export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Independent analysis puts a FGP retatrutide lot at 97.1%, against 95.4% on the certificate
The result is unremarkable. What the report omits is not.